Strong Botox sales boost Allergan profit
May 1 (Reuters) - Allergan Inc, maker of the Botox anti-wrinkle treatment, posted a stronger-than-expected quarterly profit, helped by strong sales of its eye-care drugs and Botox, which was recently also approved for treating migraine headaches.
Net income for the first quarter fell to $12.5 million, or 4 cents per share, due to a loss of $259 million from its discontinued operations. Profit was $229.8 million, or 74 cents per share, a year earlier.
Excluding special items, Allergan earned 98 cents per share. Analysts were expecting 96 cents, according to Thomson Reuters I/B/E/S.
- Radar showed missing plane may have turned back: Malaysia military
- Missing Malaysian jet may have disintegrated in mid-air: source |
- Malaysian plane presumed crashed; questions over false IDs |
- Exclusive: Malaysia plane probe narrows on mid-air disintegration - source